ReviewCurrent drug discovery technologies2008
RANKL/RANK/OPG: key therapeutic target in bone oncology.
Review in Current drug discovery technologies, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 49 citations in OpenAlex.
- Soufeng sanjie formula alleviates bone erosion in CIA mice via inhibiting RANKL/NF-κB signaling pathway and ameliorates the RA symptom in patients.Frontiers in pharmacology · 2025Article
- Does Microwave Exposure at Different Doses in the Pre/Postnatal Period Affect Growing Rat Bone Development?Physiological research · 2024Article
- Review
- Medium to long term follow-up of survival and quality of life in patients with primary tumors of the cervical spine: Experience From a large single center.Frontiers in surgery · 2022Article
- The effect of low-level laser radiation and doxycycline on the levels of osteoprotegerin and receptor activator of nuclear factor kappa-B ligand.Lasers in medical science · 2020Article
- LPS-induced inflammation disorders bone modeling and remodeling by inhibiting angiogenesis and disordering osteogenesis in chickens.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020Article
- Nm23-H1 inhibits lung cancer bone-specific metastasis by upregulating miR-660-5p targeted SMARCA5.Thoracic cancer · 2020Article
- Salidroside Improves Bone Histomorphology and Prevents Bone Loss in Ovariectomized Diabetic Rats by Upregulating the OPG/RANKL Ratio.Molecules (Basel, Switzerland) · 2018Article
- Effect and mechanism of pyrroloquinoline quinone on anti-osteoporosis in Bmi-1 knockout mice-Anti-oxidant effect of pyrroloquinoline quinone.American journal of translational research · 2017Article
- The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease.Current osteoporosis reports · 2016Review
- RANK pathway in giant cell tumor of bone: pathogenesis and therapeutic aspects.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- Osteoprotegerin Induces Apoptosis of Osteoclasts and Osteoclast Precursor Cells via the Fas/Fas Ligand Pathway.PloS one · 2015Article
- Detection of rankl positive cells in gingival tissue in healthy & chronic periodontal disease patients-a comparative study.Journal of clinical and diagnostic research : JCDR · 2014Article
- RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization.Endocrine-related cancer · 2014Article
- hRpn13, a newly identified component of the 19S particle, regulates proliferation, differentiation, and function in the human osteoblast-like cell line MG63. [corrected].Journal of physiology and biochemistry · 2012Article
- Green tea and bone health: Evidence from laboratory studies.Pharmacological research · 2011Review
- Collagenous and non-collagenous biochemical markers of bone metastases from prostate cancer.Hippokratia · 2010Article
- Therapeutic implications of osteoprotegerin.Cancer cell international · 2009Article
- Green tea and bone metabolism.Nutrition research (New York, N.Y.) · 2009Review
- Primary bone tumors of the spine revisited: A 10-year single-center experience of the management and outcome in a neurosurgical department.Journal of craniovertebral junction & spineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the major leading causes of death all over the world. Primary and secondary bone tumors can significantly deteriorate the quality of life (QOL) and the activity of daily living (ADL) of the patients. These unwelcome diseases become a social and economic burden seriously. Thus, more effective therapies for both primary and secondary bone tumors are actually required. Bone homeostasis depends on the strictly balanced activities between bone formation by osteoblasts and bone resorption by osteoclasts. Imbalance of bone formation and resorption results in various bone diseases. Both primary and secondary bone tumors develop in the unique environment bone, it is therefore necessary to understand bone cell biology in tumoral bone environment. Recent findings strongly revealed the significant involvement of the receptor activator of nuclear factor kappaB ligand (RANKL)/RANK/osteoprotegerin (OPG) triad, the key regulators of bone remodeling in bone oncology. Indeed, RANKL/RANK blocking successfully prevented the development of bone metastases. Furthermore, some cancer cells express RANK which is involved in tumor cell migration. Thus, the regulation of this triad will be a rational, encouraged therapeutic hot spot in bone oncology. In this review, we summarize the accumulating knowledge of the RANKL/RANK/OPG triad and discuss about its therapeutic capability in primary and secondary bone tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.